Sector
PharmaceuticalsOpen
₹36.71Prev. Close
₹36.77Turnover(Lac.)
₹3.94Day's High
₹37.4Day's Low
₹35.6752 Week's High
₹92.9552 Week's Low
₹34.8Book Value
₹6.28Face Value
₹2Mkt Cap (₹ Cr.)
309.45P/E
37.54EPS
1Divi. Yield
021 Jul 2023
12:00 AM
AGM
Announcement Date: 21 Jul, 2023
30 Apr 2024
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 16.6 | 16.6 | 4.15 | 4.15 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 27.25 | 19.98 | 28.31 | 25.72 |
Net Worth | 43.85 | 36.58 | 32.46 | 29.87 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Revenue | 122.38 | 88.63 | 97.68 | 61.02 |
yoy growth (%) | 38.07 | -9.26 | 60.07 | 12.14 |
Raw materials | -92.18 | -67.18 | -79.51 | -43.49 |
As % of sales | 75.32 | 75.79 | 81.39 | 71.27 |
Employee costs | -4.5 | -3.82 | -3.32 | -3.89 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 3.68 | 2.21 | 2.17 | 1.87 |
Depreciation | -1.65 | -1.66 | -1.51 | -1 |
Tax paid | -1.09 | -0.58 | -0.6 | -0.65 |
Working capital | 4.23 | 0.44 | -0.99 | 0.33 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 38.07 | -9.26 | 60.07 | 12.14 |
Op profit growth | 84.04 | 2.82 | -20.63 | -13.15 |
EBIT growth | 40.72 | 3.84 | -6.98 | 2.24 |
Net profit growth | 58.96 | 3.83 | 28.67 | -25.05 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.65 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,519.8 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.5 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.45 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,636 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Wholetime Director
Haresh Mehta
Managing Director
Harshit Mehta
Director
Rita Mehta
Whole-time Director
Rishit Mehta
Independent Director
Deepak Vekaria
Independent Director
Ramesh Rughani
Independent Director
Bharat Rathod
Company Sec. & Compli. Officer
Dinesh Modi
Independent Director
Deepesh Shah
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Medico Remedies Ltd
Summary
Medico Remedies Limited was incorporated as a Private Limited Company with the name Medico Remedies Private Limited on March 18, 1994. The status was changed to a Public Limited Company and the Company name was changed to Medico Remedies Limited on March 6, 2017. Medico Remedies is a pharmaceutical formulation manufacturing company with manufacturing and marketing capabilities in formulation with focus on anti-infective, Beta-Lactums, cephalosporins, antimalarial, antiretroviral, anti-ulcer drugs and antacids, vitamins, haematinics and other supplements. Further in addition to above, the Company also has manufacturing and marketing capabilities in other drugs such as NSAIDS, Antihistaminic, Antidiabetics, Cardio Vascular Drugs, Diuretics, Anti-Epileptics, combination drug kits, syrups and cream & gel for various therapeutic segments.The Company is ISO 9001:2015 certified for its management system for the manufacture and marketing of pharmaceutical products. It also obtained a WHO-GMP accreditation for the manufacture of its products from the World Health Organisation and has also been certified by Government Recognised Star Exports, Pharmacy and Poison Board, NAFDAC and National Drug Authority, Uganda.The Company began its operations in 1994 with manufacturing and servicing of diuretics, anti-malarials, NSAIDS tablets, anti-reterovirals, anti-ulcer drugs and anti-acids tablets. Over the years the company has expanded its scale and scope of operations and currently the Company
Read More
What is the Medico Remedies Ltd share price today?
The Medico Remedies Ltd shares price on N/A is Rs.₹37 today.
What is the Market Cap of Medico Remedies Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Medico Remedies Ltd is ₹307.04 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Medico Remedies Ltd?
The PE and PB ratios of Medico Remedies Ltd is 37.54 and 5.95 as of 22 Jul ‘24
What is the 52 Week High and Low of Medico Remedies Ltd?
The 52-week high/low is the highest and lowest price at which a Medico Remedies Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Medico Remedies Ltd is ₹35 and ₹92.87 as of 22 Jul ‘24
What is the CAGR of Medico Remedies Ltd?
Medico Remedies Ltd's CAGR for 5 Years at 54.31%, 3 Years at 62.49%, 1 Year at -52.42%, 6 Month at -56.74%, 3 Month at -21.64% and 1 Month at -5.32%.
What is the shareholding pattern of Medico Remedies Ltd?
The shareholding pattern of Medico Remedies Ltd is as follows:
Promoters - 73.34 %
Institutions - 1.19 %
Public - 25.47 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
